U.S., Oct. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07203404) titled 'A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.' on Sept. 23.
Brief Summary: An Exploratory, Single-Arm, Open-Label, Dose-Escalation Study of the Safety, Tolerability, PK, PD, and Efficacy of Anti-CD19/BCMA Universal CAR-T Therapy RD06-05 in Autoimmune Diseases (including SLE/LN, AAV/AAGN, Anti-GBM, MN, SSc, and IIM).
Study Start Date: July 24
Study Type: INTERVENTIONAL
Condition:
SLE
LN
ANCA Associated Vasculitis
ANCA-Associated Glomerulonephritis
Anti-GBM Disease
MN
SSc
IIM
Intervention:
DRUG: RD06-05 CART Cell Injection
CAR T-cell therapy administered intravenously after ...